Search
Selected Filter
Displaying 1–10 of 221 diseases results
-
Sepul Bio’s LCA10 RNA Therapy Moves into Phase 3 Clinical Trial
Research NewsThe emerging therapy improved vision for some participants in an earlier clinical trial.
-
Research News
Durable vision improvements were also observed out to 18 months for previously dosed adult patients in the trial.
-
Eye on the Cure Podcast | Episode 92: Lance Baldo, MD
Eye on the CureLance Baldo, MD, CEO at Beacon Therapeutics, is discussing his company’s gene therapy for XLRP.
-
A Family United: Thomas’ Hero’s Journey with CRB1
Beacon StoriesWhen Becky’s son Thomas was diagnosed with a rare CRB1-associated disease, their family’s world changed. But today, Becky and Thomas are embracing advocacy, community, and research as they work to raise awareness and fuel progress toward treatments and cures.
-
Nacuity’s Antioxidative Therapy NACA Performs Encouragingly in Phase 1/2 Clinical Trial
Research NewsNACA is a gene-agnostic, oral medication designed to preserve vision in people with retinitis pigmentosa and Usher syndrome.
-
Beacon Stories
Maverick, a determined and adventurous 11-year-old, was diagnosed with X-linked retinoschisis (XLRS) at age six, which led his family to find support and resources through the Foundation Fighting Blindness. Since his diagnosis, Mav continues to pursue his passions in sports and outdoor activities, inspiring his family with his resilience and positive attitude.
-
Eye on the Cure Podcast | Episode 91: Dr. George Magrath
Eye on the CureDr. George Magrath is the CEO of Opus Genetics, a clinical-stage biopharmaceutical company developing gene and small molecule therapies for vision-threatening eye diseases.
-
Beacon Stories
Lindsey Rambo once believed treatment was meant for someone else. Today, she’s the first participant in a groundbreaking gene therapy trial for LCA5—and her journey is lighting the way for what’s possible in the future of vision research.
-
Opus Genetics Receives FDA Clearance to Launch Clinical Trial for Best1 Gene Therapy
Research NewsThe Foundation funded earlier, proof-of-concept studies for the Best1 gene therapy and later launched Opus to develop several IRD gene therapies.
-
jCyte Launches New Phase 2 Clinical Trial for its Cell-Based RP Therapy
Research NewsThe trial is evaluating a cell dose that is 50 percent higher than the highest dose used in a previous Phase 2b trial.
